Abbott Laboratories' (NYSE:ABT) Institutional Investors Lost 5.9% Over the Past Week but Have Profited From Longer-term Gains
Oppenheimer Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $134
Citigroup Adjusts Abbott Laboratories Price Target to $155 From $160, Maintains Buy Rating
Express News | Baxter Down 5.5%, Abbott Down 2.3%, Becton Dickinson Down 2.9%, Illumina Down 5.3%, Dexcom Down 2.2%, Medtronic Down 2.1%, Stryker Down 3.5%
Express News | Shares of Medical Device Makers Fall Amid Broad Market Selloff
Express News | Abbott : Citigroup Cuts Target Price to $155 From $160
